Skip to main navigation
Skip to search
Skip to main content
Research @ Flinders Home
Search content at Research @ Flinders
Home
Profiles
Research Units
Research Outputs
Projects
Student theses
Activities
Prizes
Equipment
Omalizumab-induced ocular myasthenia gravis?
Hanru Wang
, Devaraj Supramaniam
, Sudha Cugati
,
Celia Chen
College of Medicine and Public Health
Research output
:
Contribution to journal
›
Letter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Omalizumab-induced ocular myasthenia gravis?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Myasthenia gravis
100%
Omalizumab
100%
Immunoglobulin E
66%
B Lymphocyte
33%
Immunoglobulin G1
33%
Therapeutic Agent
33%
Neuromuscular Transmission
33%
Allergic Asthma
33%
Monoclonal Antibody
33%
Pharmacology, Toxicology and Pharmaceutical Science
Omalizumab
100%
Myasthenia gravis
100%
Immunoglobulin E
66%
Recombinant DNA
33%
Monoclonal Antibody
33%
Allergic Asthma
33%
Myasthenia Like Syndrome
33%
Immunoglobulin G1
33%
Neuroscience
Myasthenia gravis
100%
Omalizumab
100%
Immunoglobulin E
66%
Monoclonal Antibody
33%
Neuromuscular Transmission
33%
B Cell
33%
Recombinant DNA
33%
Immunoglobulin G1
33%
Immunology and Microbiology
Omalizumab
100%
Myasthenia gravis
100%
Immunoglobulin E
66%
B Cell
33%
Monoclonal Antibody
33%
Immunoglobulin G1
33%
Allergic Asthma
33%